Adolescents Archives - Page 4 of 5

This document summarizes the results of the WHO-commissioned full value proposition for new TB vaccines. It is for use by national and global decision-makers involved in vaccine development and implementation.

Evidence considerations for vaccine policy development for tuberculosis vaccines intended for adults and adolescents

The ECVP facilitates early engagement and alignment across the stakeholders involved in vaccine development and those responsible for vaccine regulatory, policy, funding and country introduction decisions. This framework aims to anticipate and collectively delineate the clinical trial, observational, and other data likely to be required by global and national policymakers, and to do so when most valuable – during development of the late-stage clinical plan, including the design of the pivotal licensure trial.

A global framework to prepare for country introduction of new TB vaccines for adults and adolescents

New vaccines for the prevention of TB disease in adolescents and adults could become available in the next 3-5 years. WHO has therefore developed a Global Framework to prepare for Country Introduction of New TB Vaccines for Adults and Adolescents which aims to guide countries and global stakeholders in preparing for the introduction and scale-up in countries. This framework has been drafted in collaboration with a WHO Expert Advisory Group and in consultation with other stakeholders, and describes critical activities to prepare for introduction decision-making and subsequent implementation and impact of new TB vaccines for adults and adolescents.

Preferred product characteristics for new tuberculosis vaccine

2018

The document presents WHO preferences for new tuberculosis vaccines, driven by the high medical need for contribution to the fight against TB, in alignment with the End TB strategy. Priorities are for a vaccine to be administered to adolescents and adults for prevention of pulmonary tuberculosis and reduction of transmission, and for a pediatric vaccine with improved safety and efficacy as compared to BCG.

The impact of alternative delivery strategies for novel tuberculosis vaccines in low-income and middle-income countries: a modelling study

We estimated the impact of novel tuberculosis vaccines in low-income and middle-income countries (LMICs) in several delivery scenarios.

The cost and cost-effectiveness of novel tuberculosis vaccines in low- and middle-income countries: A modeling study

We assessed future costs, cost-savings, and cost-effectiveness of introducing novel TB vaccines in low- and middle-income countries (LMICs) for a range of product characteristics and delivery strategies.

The potential impact of novel tuberculosis vaccines on health equity and financial protection in low-income and middle-income countries

BCG revaccination, Hypothetical vaccines

We assessed the potential financial risk protection from introducing novel TB vaccines, and how health and economic benefits would be distributed across income quintiles.

ACEITar: Evaluation of the acceptability of new and repurposed tuberculosis vaccines in Mozambique

2022-2024

Ongoing

This is a mixed-methods study collecting information on willingness to receive a new TB vaccine among adolescents, their caretakers, and adults in Mozambique, a high TB burden country, to assess potential barriers to high uptake of new TB vaccines.

Potential implementation strategies, acceptability, and feasibility of new and repurposed TB vaccines

2022

BCG revaccination, M72/AS01e